Serum human trophoblast cell surface antigen and T-box protein 5 levels play a role in predicting adverse pregnancy outcomes in eclampsia
Trop-2 and TBX5 in predicting adverse pregnancy outcomes in eclampsia
Abstract
Objective: The levels of human trophoblast surface antigen (Trop-2) and T-box protein 5 (TBX5) in the serum of patients with preeclampsia were detected, and their value in predicting adverse pregnancy outcomes was analyzed.
Methods: A total of 196 pregnant women with preeclampsia who underwent prenatal examinations and delivered in our hospital from October 2021 to September 2024, as well as 196 healthy pregnant women, were selected as the eclampsia group and the control group, respectively. The 196 pregnant women with preeclampsia were divided into two groups according to their pregnancy outcome: the adverse outcome group and the good outcome group. Using the enzyme-linked immunosorbent assay (ELISA), the levels of serum Trop-2 and TBX5 were measured. Using multivariate logistic regression analysis, the factors impacting the various pregnancy outcomes of preeclamptic pregnant women were examined.
Results: Compared with control group, the serum TBX5 levels in the eclampsia group (20.86±6.45 µg/L vs. 15.34±5.07 µg/L), as well as diastolic blood pressure, FBG, 24-hour urine protein, TG, systolic blood pressure and TC, were significantly greater. The levels of Trop-2 [(5.46±1.72) µg/L vs. (7.37±2.08) µg/L]. The total incidences of preterm infants, fetal distress, placental abruption and adverse pregnancy outcomes in the eclampsia group were significantly greater than those in the control group (P<0.05). The serum TBX5 level in the adverse outcome group [(23.01±6.66) µg/L vs. (19.53±6.32) µg/L], as well as diastolic blood pressure, FBG, 24-hour urine protein, TG, systolic blood pressure, and TC, were significantly greater than those in the good outcome group. The levels of Trop-2 [(4.90±1.61) µg/L vs. (5.81±1.79) µg/L] and HDL-C decreased significantly (P<0.05); Trop-2 [OR 95% CI: 0.38 (0.28,0.53)], TBX5 [OR 95% CI: 3.89 (1.88,8.04)] and 24-hour urine protein [OR: 3.14 (1.82,5.42)] were influencing factors for the pregnancy outcome of pregnant women with preeclampsia (P<0.05); and the AUCs of serum Trop-2, TBX5 and their combination in predicting the pregnancy outcome of pregnant women with preeclampsia were 0.79, 0.76 and 0.90, respectively. The combined prediction of the two had a greater predictive value than did Trop-2 or TBX5 alone (all P<0.05).
Conclusion: The serum Trop-2 level of pregnant women with preeclampsia is abnormally low, and the TBX5 level is abnormally high. The combination of the two can be used as a biological indicator for evaluating adverse pregnancy outcomes.
References
2.Ormesher L, Vause S, Higson S, Roberts A, Clarke B, Curtis S, Ordonez V, Ansari F, Everett TR, Hordern C, Mackillop L, Stern V, Bonnett T, Reid A, Wallace S, Oyekan E, Douglas H, Cauldwell M, Reddy M, Palmer K, Simpson M, Brennand J, Minns L, Freeman L, Murray S, Mary N, Castleman J, Morris KR, Haslett E, Cassidy C, Johnstone ED, Myers JE. Prevalence of preeclampsia and adverse pregnancy outcomes in women with preexisting cardiomyopathy: a multicenter retrospective cohort study. Sci Rep. 2023 Jan 4;13(1):153.
3.Darmochwal-Kolarz D, Chara A. The Association of IL-17 and PlGF/sENG Ratio in Pre-Eclampsia and Adverse Pregnancy Outcomes. Int J Environ Res Public Health. 2022 Dec 31;20(1):768.
4.Eslamzadeh A, Kashani SMA, Asadi N, Bazmi S, Rezaei S, Karimimoghadam Z, Nowrouzi-Sohrabi P, Tabrizi R. Serum Calcium and Magnesium Levels in Women Presenting with Preeclampsia: A Systematic Review and Meta-analysis Based on Observational Studies. Galen Med J. 2023 Dec 18;12:e3151.
5.Keepanasseril A, Bharathi V, Bobby Z, Kar SS, Parameswaran S, Pillai AA, Maurya DK. Serum biomarkers of maternal morbidity and adverse outcome in severe preeclampsia. Eur J Obstet Gynecol Reprod Biol. 2022 Mar;270:190-194.
6.Bayor F, Adu-Bonsaffoh K, Antwi-Boasiako C. Maternal serum angiopoietins levels in preeclampsia and pregnancy outcomes. Health Sci Rep. 2024 Jan 15;7(1):e1806.
7.Barron A, Manna S, McElwain CJ, Musumeci A, McCarthy FP, O'Keeffe GW, McCarthy CM. Maternal preeclampsia serum increases neurite growth and mitochondrial function through a potential IL-6-dependent mechanism in differentiated SH-SY5Y cells. Front Physiol. 2023 Jan 12;13:1043481.
8.Tesfa E, Munshea A, Nibret E, Gizaw ST. Association of maternal serum magnesium with preeclampsia in African pregnant women: a systematic review and meta-analysis. Int Health. 2024 Jan 2;16(1):14-22.
9.Tesfa E, Munshea A, Nibret E, Gizaw ST. Association of maternal serum magnesium with preeclampsia in African pregnant women: a systematic review and meta-analysis. Int Health. 2024 Jan 2;16(1):14-22.
10.Sakcak B, Turgut E, Denizli R, Farisogullari N, Tanacan A, Yazihan N, Sahin D. Comparison of serum midkine levels between pregnant women with and without preeclampsia: A case‒control study from a tertiary hospital. Int J Gynecol Obstet. 2023 Jul;162(1):287-291.
11.Farahani M, Sharifinejad N, Hashemnejad M, Mashak B, Mahboubipour H, Farahani M, Rastad H, Nirouei M. The effect of magnesium sulfate on maternal serum electrolytes and parathyroid hormone in preeclampsia. Int J Gynecol Obstet. 2022 Dec;159(3):938-943.
12.Wu L, Zheng Y, Liu J, Luo R, Wu D, Xu P, Wu D, Li X. Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19. Aging (Albany NY). 2021 Apr 20;13(8):10833-10852.
13.Moharana JJ, Mishra R, Nayak AK. A Study on Serum Lactate Dehydrogenase and Uric Acid in Preeclampsia and Eclampsia: Can they Predict Adverse Fetomaternal Outcome? Int J Appl Basic Med Res. 2023 Apr-Jun;13(2):95-100.
14.Wu L, Zhong Y, Wu D, Xu P, Ruan X, Yan J, Liu J, Li X. Immunomodulatory Factor TIM3 of Cytolytic Active Genes Affected the Survival and Prognosis of Lung Adenocarcinoma Patients by Multi-Omics Analysis. Biomedicines. 2022 Sep 10;10(9):2248.
15.Abdelrahiem SK, Ahmed ABA, Sharif ME, Adam I. Association between maternal serum 25-hydroxyvitamin D concentrations and the risk of preeclampsia in central Sudan: a case‒control study. Trans R Soc Trop Med Hyg. 2022 May 2;116(5):487-491.
16.Ning W, Chen Y, Chen Y, Zhang H, Wu B, Wen C. Correlation and predictive value of serum miR-146b-5p expression during the first trimester of pregnancy with preeclampsia. J Obstet Gynecol. 2022 Nov;42(8):3537-3544.
17.Wu L, Liu Q, Ruan X, Luan X, Zhong Y, Liu J, Yan J, Li X. Multiple Omics Analysis of the Role of RBM10 Gene Instability in Immune Regulation and Drug Sensitivity in Patients with Lung Adenocarcinoma (LUAD). Biomedicines. 2023 Jun 29;11(7):1861.
18.Tapasvi I, Rajora P, Tapasvi C, Sethi A, Grover S. A Comparative Study of Serum and Salivary Uric Acid Measurement in Preeclampsia and Normal Pregnancy in a Tertiary Care Hospital in Punjab: A Pilot Study. Cureus. 2023 Nov 7;15(11):e48457.
19.Liu Y, Ma S, Huang X, Bo Y, Fu W, Cao Y, Duan D, Dou W, Zeng F, Wang X, Gong M, Zhang X, Lyu Q, Zhao X. Dietary intake and serum concentrations of vitamin A and vitamin E and preeclampsia risk in Chinese pregnant women: A matched case‒control study. Front Nutr. 2023 Mar 30;10:1049055.
20.Wu L, Zheng Y, Ruan X, Wu D, Xu P, Liu J, Wu D, Li X. Long-chain noncoding ribonucleic acids affect the survival and prognosis of patients with esophageal adenocarcinoma through the autophagy pathway: construction of a prognostic model. Anticancer Drugs. 2022 Jan 1;33(1):e590-e603.
21.Uddin SMN, Haque M, Barek MA, Chowdhury MNU, Das A, Uddin MG, Islam MS. Analysis of serum calcium, sodium, potassium, zinc, and iron in patients with preeclampsia in Bangladesh: A case‒control study. Health Sci Rep. 2023 Feb 2;6(2):e1097.
22.Xiang Q, Chen Y, Gu X, Yang Y, Wang Y, Zhao Y. The correlation between maternal serum sST2, IL-33 and NT-proBNP concentrations and occurrence of preeclampsia in twin pregnancies: A longitudinal study. J Clin Hypertens (Greenwich). 2022 Nov;24(11):1516-1523.
23.Wu L, Zhong Y, Yu X, Wu D, Xu P, Lv L, Ruan X, Liu Q, Feng Y, Liu J, Li X. Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research. Anticancer Drugs. 2022 Oct 1;33(9):943-959.
24.Shaheen A, Luqman MW, Iqbal S, Khan N, Fatima S, Nazli R. Relationship Of Serum Visfatin Levels With Serum Electrolytes, Liver Profile, Hepatic Enzymes And Anthropometric Parameters In Pregnant Women With Preeclampsia And Eclampsia During 3rd Trimester. J Ayub Med Coll Abbottabad. 2022 Jan-Mar;34(1):62-66.
25.Sokratous N, Bednorz M, Syngelaki A, Wright A, Nicolaides KH, Kametas NA. Prediction using serum glycosylated fibronectin and angiogenic factors of superimposed preeclampsia in women with chronic hypertension. Ultrasound Obstet Gynecol. 2023 Dec;62(6):836-842.
26.Sokratous N, Wright A, Syngelaki A, Kakouri E, Laich A, Nicolaides KH. Screening for preeclampsia by maternal serum glycosylated fibronectin and angiogenic markers at 36 weeks' gestation. Ultrasound Obstet Gynecol. 2024 Jan;63(1):88-97.
27.Tesfa E, Munshea A, Nibret E, Mekonnen D, Sinishaw MA, Gizaw ST. Maternal serum uric acid, creatinine and blood urea levels in the prediction of preeclampsia among pregnant women attending ANC and delivery services at Bahir Dar city public hospitals, northwest Ethiopia: A case‒control study. Heliyon. 2022 Oct 14;8(10):e11098.
28.Kasoha M, Takacs Z, Dumé J, Findeklee S, Gerlinger C, Sima RM, Ples L, Solomayer EF, Haj Hamoud B. Postpartum Assessment of the Correlation between Serum Hormone Levels of Estradiol, Progesterone, Prolactin and ß-HCG and Blood Pressure Measurements in Pre-Eclampsia Patients. Diagnostics (Basel). 2022 Jul 12;12(7):1700.
29.Kabodmehri R, Ghanami Gashti N, Zahiri Sorouri Z, Sharami SH, Milani F, Hasanpour M, Eslami-Kenarsari H, Rafiei Sorouri Z. Levels of serum β-human chorionic gonadotropin after embryo transfer and subsequent miscarriage, preeclampsia, and intrauterine growth restriction. Health Sci Rep. 2024 Apr 10;7(4):e2015.
Copyright (c) 2025 Yao Li, Sutong Huang, Yan Xuan, Hao Shen, Weiwei Zhang, Jia Li
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.